Skip to main content

Advertisement

SpringerLink
Log in

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma

  • Clinical study - patient study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We report the case of a 75-year old woman who received sorafenib (Nexavar®, Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cohen H, McGovern F (2005) Renal Cell carcinoma. N Engl J Med 353:3477–3490

    Google Scholar 

  2. Flanigan RC, Mickisch G, Sylvester R et al (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076. doi:10.1097/01.ju.0000110610.61545.ae

    Article  PubMed  Google Scholar 

  3. Gerstner ER, Fine RL (2007) Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16):2306–2312. doi:10.1200/JCO.2006.10.0677

    Article  PubMed  Google Scholar 

  4. Costa LJ, Drabkin HA (2007) Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12:1404–1415. doi:10.1634/theoncologist.12-12-1404

    Article  PubMed  CAS  Google Scholar 

  5. Chang YS, Henderson A, Xue D et al (2005) BAY 43-9006 (Sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. Proc Am Assoc Cancer Res: 46. Abstract

  6. Strumberg D, Clark JW, Awada A et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426–437. doi:10.1634/theoncologist.12-4-426

    Article  PubMed  CAS  Google Scholar 

  7. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512. doi:10.1200/JCO.2005.03.6723

    Article  PubMed  CAS  Google Scholar 

  8. Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463. doi:10.1200/JCO.2004.06.132

    Article  PubMed  Google Scholar 

  9. Bracarda S, Caserta C, Sordini L et al (2007) Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Ann Oncol 18(Suppl 6):vi22–vi25. doi:10.1093/annonc/mdm219

    Article  PubMed  Google Scholar 

  10. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109. doi:10.1158/0008-5472.CAN-04-1443

    Article  PubMed  CAS  Google Scholar 

  11. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875. doi:10.1056/NEJM199609193351207

    Article  PubMed  CAS  Google Scholar 

  12. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomised discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512. doi:10.1200/JCO.2005.03.6723

    Article  PubMed  CAS  Google Scholar 

  13. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134. doi:10.1056/NEJMoa060655

    Article  PubMed  CAS  Google Scholar 

  14. Massard C, Zonierek J, Laplanche A et al (2006) Incidence of brain metastasis in advanced renal cell carcinoma among patients randomised in a phase III trial of sorafenib, an oral multi-kinase inhibitor. Ann Oncol 17:148–149 (suppl 9, abstr 454P)

    Article  Google Scholar 

  15. Medioni J, Cojocarasu O, Belcaceres JL et al (2007) Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 18(7):1282–1283. doi:10.1093/annonc/mdm275

    Article  PubMed  CAS  Google Scholar 

  16. Trinh QD, Cardinal E, Gallina A et al (2006) Sunitinib relieves renal cell carcinoma spinal cord compression. Eur Urol 51(6):1741–1743. doi:10.1016/j.eururo.2006.10.050

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Spedali Civili di Brescia, Brescia, Italy

    Francesca Valcamonico, Vittorio Ferrari, Vito Amoroso, Giovanni Rangoni, Edda Simoncini, Patrizia Marpicati, Lucia Vassalli, Salvatore Grisanti & Giovanni Marini

Authors
  1. Francesca Valcamonico
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vittorio Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vito Amoroso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giovanni Rangoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edda Simoncini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patrizia Marpicati
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lucia Vassalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Salvatore Grisanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giovanni Marini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesca Valcamonico.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valcamonico, F., Ferrari, V., Amoroso, V. et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 91, 47–50 (2009). https://doi.org/10.1007/s11060-008-9676-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9676-4

Keywords

Search

Navigation